Drawing for CYTOCENTRIC PLATFORM

USPTO serial 98701386

CYTOCENTRIC PLATFORM

Reviewed by CopyMark Law Group

Status 748
Filing date
Status date
Registration date
—
Examiner
HOFFMAN, DAVID AARON
Law office
TMEG LAW OFFICE 107

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with CYTOCENTRIC PLATFORM?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Nancy A. Del Pizzo

Nancy A. Del Pizzo Rivkin Radler LLP25 Main StreetCourt Plaza North, Suite 501Hackensack, NJ 07601

Goods and services

ClassDescriptionStatusFirst use
010Cell culture apparatus for medical use, namely, cell culture incubation and processing systems comprised of cell culture processing chambers, isolation chambers, glove boxes, incubation chambers, buffer chambers, and clean hoods that allow control of critical parameters necessary for cell culture for medical useACTIVEJun 17, 2026

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Aug 22, 2026SUPCSTATEMENT OF USE PROCESSING COMPLETE—
Aug 22, 2026AITUCASE ASSIGNED TO INTENT TO USE PARALEGAL—
Jun 18, 2026EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Jun 17, 2026IUAFUSE AMENDMENT FILED—
Jun 17, 2026EISUTEAS STATEMENT OF USE RECEIVEDThe applicant filed a Statement of Use with specimens showing the mark in actual commerce. The USPTO will review the filing for compliance. If accepted, the mark can proceed to registration; if deficient, the USPTO may issue a requirement or office action.
Jun 17, 2026EX2GSOU EXTENSION 2 GRANTED—
Jun 17, 2026EXT2SOU EXTENSION 2 FILED—
Jun 17, 2026EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Dec 18, 2025EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Dec 17, 2025EX1GSOU EXTENSION 1 GRANTED—
Dec 17, 2025EXT1SOU EXTENSION 1 FILED—
Dec 17, 2025EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Jun 17, 2025NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Apr 22, 2025NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Apr 22, 2025PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Apr 16, 2025NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Mar 24, 2025CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Mar 24, 2025TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Mar 24, 2025CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Mar 24, 2025TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Mar 12, 2025TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Mar 12, 2025ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Mar 12, 2025REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Mar 3, 2025GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Mar 3, 2025GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Mar 3, 2025CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Feb 28, 2025DOCKASSIGNED TO EXAMINER—
Feb 27, 2025NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Jan 10, 2025TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Jan 10, 2025ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Jan 10, 2025REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Aug 16, 2024NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance